UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Infections due to Serratia species

Authors
Rebekah Moehring, MD, MPH
Steven Mahlen, PhD, D(ABMM)
Section Editor
Stephen B Calderwood, MD
Deputy Editor
Allyson Bloom, MD

INTRODUCTION

Serratia species are gram-negative bacilli of the Enterobacteriaceae group of bacteria, although they are not a common component of healthy human fecal flora. In the early part of the 20th century, Serratia marcescens was considered a nonpathogenic organism and was used in medical experiments and as a biological warfare test agent [1]. Since the mid-1970s, however, Serratia species have been recognized to cause a full spectrum of human clinical disease. Additionally, Serratia species may harbor multidrug resistance mechanisms that can complicate treatment decisions.

This article will review the microbiology, epidemiology, clinical features, diagnosis, and treatment of infections caused by Serratia species.

Detailed discussion of particular infectious syndromes (eg, complicated cystitis or hospital-acquired pneumonia) that Serratia can cause can be found separately in topics dedicated to that syndrome:

(See "Acute complicated cystitis and pyelonephritis".)

(See "Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults" and "Treatment of hospital-acquired and ventilator-associated pneumonia in adults".)

                      

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Aug 01 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Mahlen SD. Serratia infections: from military experiments to current practice. Clin Microbiol Rev 2011; 24:755.
  2. Genus Serratia. List of Prokaryotic names with Standing in Nomenclature. http://www.bacterio.net/serratia.html (Accessed on July 31, 2016).
  3. Bizio B. Lettera di Bartolomeo Bizio al Chiarissimo canonico Angelo Bellani sopra il fenomeno della polenta porporina. Bibl Ital G Lett Sci Art 1823; VIII:275.
  4. Laupland KB, Parkins MD, Gregson DB, et al. Population-based laboratory surveillance for Serratia species isolates in a large Canadian health region. Eur J Clin Microbiol Infect Dis 2008; 27:89.
  5. Horcajada JP, Martínez JA, Alcón A, et al. Acquisition of multidrug-resistant Serratia marcescens by critically ill patients who consumed tap water during receipt of oral medication. Infect Control Hosp Epidemiol 2006; 27:774.
  6. Ehrenkranz NJ, Bolyard EA, Wiener M, Cleary TJ. Antibiotic-sensitive Serratia marcescens infections complicating cardiopulmonary operations: contaminated disinfectant as a reservoir. Lancet 1980; 2:1289.
  7. Archibald LK, Corl A, Shah B, et al. Serratia marcescens outbreak associated with extrinsic contamination of 1% chlorxylenol soap. Infect Control Hosp Epidemiol 1997; 18:704.
  8. Buffet-Bataillon S, Rabier V, Bétrémieux P, et al. Outbreak of Serratia marcescens in a neonatal intensive care unit: contaminated unmedicated liquid soap and risk factors. J Hosp Infect 2009; 72:17.
  9. Boulton FE, Chapman ST, Walsh TH. Fatal reaction to transfusion of red-cell concentrate contaminated with Serratia liquefaciens. Transfus Med 1998; 8:15.
  10. Duncan KL, Ransley J, Elterman M. Transfusion-transmitted Serratia liquifaciens from an autologous blood unit. Transfusion 1994; 34:738.
  11. Ramírez-Arcos S, Chin-Yee I, Hume H, et al. Fatal septic shock associated with transfusion-transmitted Serratia marcescens. Transfusion 2006; 46:679.
  12. Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995; 333:147.
  13. Sunenshine RH, Tan ET, Terashita DM, et al. A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy. Clin Infect Dis 2007; 45:527.
  14. Blossom D, Noble-Wang J, Su J, et al. Multistate outbreak of Serratia marcescens bloodstream infections caused by contamination of prefilled heparin and isotonic sodium chloride solution syringes. Arch Intern Med 2009; 169:1705.
  15. Henry B, Plante-Jenkins C, Ostrowska K. An outbreak of Serratia marcescens associated with the anesthetic agent propofol. Am J Infect Control 2001; 29:312.
  16. Gupta N, Hocevar SN, Moulton-Meissner HA, et al. Outbreak of Serratia marcescens bloodstream infections in patients receiving parenteral nutrition prepared by a compounding pharmacy. Clin Infect Dis 2014; 59:1.
  17. de Vries JJ, Baas WH, van der Ploeg K, et al. Outbreak of Serratia marcescens colonization and infection traced to a healthcare worker with long-term carriage on the hands. Infect Control Hosp Epidemiol 2006; 27:1153.
  18. Hejazi A, Aucken HM, Falkiner FR. Epidemiology and susceptibility of serratia marcescens in a large general hospital over an 8-year period. J Hosp Infect 2000; 45:42.
  19. Passaro DJ, Waring L, Armstrong R, et al. Postoperative Serratia marcescens wound infections traced to an out-of-hospital source. J Infect Dis 1997; 175:992.
  20. Voelz A, Müller A, Gillen J, et al. Outbreaks of Serratia marcescens in neonatal and pediatric intensive care units: clinical aspects, risk factors and management. Int J Hyg Environ Health 2010; 213:79.
  21. de Boer MG, Brunsveld-Reinders AH, Salomons EM, et al. Multifactorial origin of high incidence of Serratia marcescens in a cardio-thoracic ICU: analysis of risk factors and epidemiological characteristics. J Infect 2008; 56:446.
  22. van der Sar-van der Brugge S, Arend SM, Bernards AT, et al. Risk factors for acquisition of Serratia marcescens in a surgical intensive care unit. J Hosp Infect 1999; 41:291.
  23. Sikka MK, Hayden MK, Pur S, et al. Microbiologic and clinical epidemiologic characteristics of the Chicago subset of a multistate outbreak of Serratia marcescens bacteremia. Infect Control Hosp Epidemiol 2010; 31:1191.
  24. Annual epidemiological report on communicable diseases in Europe. European Centre for Disease Prevention and Control, 2010; 172.
  25. Diekema DJ, Pfaller MA, Jones RN, et al. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. Int J Antimicrob Agents 2000; 13:257.
  26. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51 Suppl 1:S81.
  27. Ishikawa K, Matsumoto T, Yasuda M, et al. The nationwide study of bacterial pathogens associated with urinary tract infections conducted by the Japanese Society of Chemotherapy. J Infect Chemother 2011; 17:126.
  28. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996.
  29. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34:1.
  30. LANCASTER LJ. Role of Serratia species in urinary tract infections. Arch Intern Med 1962; 109:536.
  31. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50:59.
  32. Chuang TY, Chuang CP, Cheng HH, Hsueh PR. Aortic valve infective endocarditis caused by Serratia liquefaciens. J Infect 2007; 54:e161.
  33. Yu VL. Serratia marcescens: historical perspective and clinical review. N Engl J Med 1979; 300:887.
  34. Mills J, Drew D. Serratia marcescens endocarditis: a regional illness associated with intravenous drug abuse. Ann Intern Med 1976; 84:29.
  35. Pegues DA, Shireley LA, Riddle CF, et al. Serratia marcescens surgical wound infection following breast reconstruction. Am J Med 1991; 91:173S.
  36. Sokalski SJ, Jewell MA, Asmus-Shillington AC, et al. An outbreak of Serratia marcescens in 14 adult cardiac surgical patients associated with 12-lead electrocardiogram bulbs. Arch Intern Med 1992; 152:841.
  37. Rehman T, Moore TA, Seoane L. Serratia marcescens necrotizing fasciitis presenting as bilateral breast necrosis. J Clin Microbiol 2012; 50:3406.
  38. Vano-Galvan S, Álvarez-Twose I, Moreno-Martín P, Jaén P. Fulminant necrotizing fasciitis caused by Serratia marcescens in an immunosuppressed host. Int J Dermatol 2014; 53:e57.
  39. Prelog T, Jereb M, Cuček I, Jazbec J. Necrotizing fasciitis caused by Serratia marcescens after venous access port implantation in a child with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2012; 34:e246.
  40. Aronson LC, Alderman SI. The Occurrence and Bacteriological Characteristics of S. marcescens from a Case of Meningitis. J Bacteriol 1943; 46:261.
  41. Cohen AL, Ridpath A, Noble-Wang J, et al. Outbreak of Serratia marcescens bloodstream and central nervous system infections after interventional pain management procedures. Clin J Pain 2008; 24:374.
  42. Civen R, Vugia DJ, Alexander R, et al. Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy. Clin Infect Dis 2006; 43:831.
  43. Dubouix A, Roques C, Segonds C, et al. Epidemiological investigation of a Serratia liquefaciens outbreak in a neurosurgery department. J Hosp Infect 2005; 60:8.
  44. Ariel I, Arad I, Soffer D. Autopsy findings of Serratia meningoencephalitis in infants. Pediatr Pathol 1986; 6:351.
  45. Campbell JR, Diacovo T, Baker CJ. Serratia marcescens meningitis in neonates. Pediatr Infect Dis J 1992; 11:881.
  46. Samonis G, Vouloumanou EK, Christofaki M, et al. Serratia infections in a general hospital: characteristics and outcomes. Eur J Clin Microbiol Infect Dis 2011; 30:653.
  47. Badenoch PR, Thom AL, Coster DJ. Serratia ficaria endophthalmitis. J Clin Microbiol 2002; 40:1563.
  48. Das S, Sheorey H, Taylor HR, Vajpayee RB. Association between cultures of contact lens and corneal scraping in contact lens related microbial keratitis. Arch Ophthalmol 2007; 125:1182.
  49. Sridhar J, Kuriyan AE, Flynn HW Jr, et al. ENDOPHTHALMITIS CAUSED BY SERRATIA MARCESCENS: Clinical Features, Antibiotic Susceptibilities, and Treatment Outcomes. Retina 2015; 35:1095.
  50. Cheng KH, Leung SL, Hoekman HW, et al. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet 1999; 354:181.
  51. Hanson ND, Sanders CC. Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. Curr Pharm Des 1999; 5:881.
  52. Sader HS, Castanheira M, Farrell DJ, et al. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). Diagn Microbiol Infect Dis 2015; 83:389.
  53. Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014; 69:266.
  54. Naumiuk L, Baraniak A, Gniadkowski M, et al. Molecular epidemiology of Serratia marcescens in two hospitals in Gdańsk, Poland, over a 5-year period. J Clin Microbiol 2004; 42:3108.
  55. Empel J, Baraniak A, Literacka E, et al. Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agents Chemother 2008; 52:2449.
  56. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Resistance Testing; 21st Informational Supplement. 2011; M100.
  57. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20:440.
  58. Silva KE, Cayô R, Carvalhaes CG, et al. Coproduction of KPC-2 and IMP-10 in Carbapenem-Resistant Serratia marcescens Isolates from an Outbreak in a Brazilian Teaching Hospital. J Clin Microbiol 2015; 53:2324.
  59. Kazmierczak KM, Rabine S, Hackel M, et al. Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2016; 60:1067.
  60. Arana DM, Saez D, García-Hierro P, et al. Concurrent interspecies and clonal dissemination of OXA-48 carbapenemase. Clin Microbiol Infect 2015; 21:148.e1.
  61. Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther 2008; 30:2040.
  62. Harris PN, Ferguson JK. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents 2012; 40:297.
  63. Choi SH, Kim YS, Chung JW, et al. Serratia bacteremia in a large university hospital: trends in antibiotic resistance during 10 years and implications for antibiotic use. Infect Control Hosp Epidemiol 2002; 23:740.
  64. Boyle RJ, Curtis N, Kelly N, et al. Clinical implications of inducible beta-lactamase activity in Gram-negative bacteremia in children. Pediatr Infect Dis J 2002; 21:935.
  65. Goldstein FW. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect 2002; 8:823.
  66. Livermore DM, Brown DF, Quinn JP, et al. Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? Clin Microbiol Infect 2004; 10:84.
  67. Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis 2013; 57:781.